Spectral AI Inc. has signed a Memorandum of Understanding (MOU) with global medical device/burn wound therapy developer
PolyNovo Limited to deploy the DeepView System on a limited basis in Australia.
PolyNovo will support Spectral AI’s application to the Australian Special Access Scheme (SAS) for deploying up to two DeepView Systems at the Royal Adelaide Hospital and The Alfred Hospital, both in Melbourne. This initial deployment will provide a foundation for the DeepView System's eventual commercial roll-out Down Under based on clinician evaluations and experiences.
The Australia's Therapeutics Goods Administration introduced the SAS in recognition that circumstances exist in which patients need access to certain medicines, medical devices, or biologics that are not already included in the Australian Register of Goods.
“PolyNovo’s therapies have proven to be life-changing and it is one of the world’s most respected providers of burn treatment solutions,” Spectral AI CEO Peter M. Carslon said. “Understanding when it is appropriate to apply these therapies is paramount to realizing improved patient outcomes. We believe the Day One wound healing assessment provided by the DeepView System empowers clinicians with the knowledge to make an informed and rapid diagnosis when time is of the essence. We are honored to work with an established market leader as we take these initial steps to familiarize clinicians in Australia with Spectral AI’s technology, support their work, and help to elevate the level of patient care.”
Spectral AI’s DeepView System is a predictive device that offers clinicians an immediate and objective assessment of a burn wound’s healing potential before treatment or other medical intervention. The image processing algorithm employed by the DeepView System uses multispectral imaging that is trained and tested against a proprietary database of more than 340 billion clinically validated data points. The DeepView System is non-invasive and cart-based, allowing for mobility within the healthcare setting.
Melbourne-based PolyNovo develops and sells patented, bioabsorbable, synthetic, polymer technology used to reconstruct complex wounds, including deep dermal and full‐thickness burns, and aid the body in generating new tissue. PolyNovo’s U.S. Food and Drug Administration-approved NovoSorb BTM (Biodegradable Temporising Matrix) and NovoSorb MTX product portfolio is available in 37 countries.
Spectral AI Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The company is working to revolutionize the management of wound care by “Seeing the Unknown” with its DeepView System, which could potentially provide faster and more accurate treatment insight towards value care and reduce healthcare costs.
(20min delay)